Mechanistic dissection of these pathways has prompted efforts to develop a standardized “TRM immunoscore” that integrates phenotypic composition (CD103, CD69, CD49a) with spatial localization relative to tumor epithelium and vasculature. This evidence concerns the gene CD69 and neoplasm.